Douglas Liu Joins QIAGEN as Vice President Global Operations
Jul 12 2005

Douglas Liu Joins QIAGEN as Vice President Global Operations

Venlo, The Netherlands, July 12, 2005 - QIAGEN, N.V. (Nasdaq: QGEN; Frankfurt , Prime Standard: QIA) today announced that Douglas Liu joined QIAGEN as Vice President Global Operations on July 1, 2005. In this role, Mr. Liu will oversee all of QIAGEN's operations including manufacturing, quality, logistics and infrastructure. Mr. Liu will be a member of QIAGEN's Executive Committee and will be based in QIAGEN's European headquarters in Hilden, Germany. He will report to Peer M. Schatz, QIAGEN's Chief Executive Officer.

Mr. Liu brings to QIAGEN twenty years of experience in leading roles in operations, strategic planning and R&D in molecular diagnostics, immunodiagnostics and other healthcare market segments. Mr. Liu joins QIAGEN from Bayer Healthcare, where he worked as Head of Operations for Nucleic Acid Diagnostics in the United States and in Strategic Planning and Consulting at Bayer AG at Bayer's Headquarters in Germany. Prior to joining Bayer, Mr. Liu held positions at Abbott Diagnostics and Chiron Diagnostics. Mr. Liu holds an MBA from Boston University and a B.S. from the University of Illinois.

In his position as QIAGEN's Vice President Global Operations, Mr. Liu will focus on enhancing QIAGEN's operational excellence in QIAGEN's global operations and on further increasing efficiencies by leveraging and synchronizing QIAGEN's world-wide operational infrastructure.

"We are very pleased that Douglas has joined our team" said Peer M. Schatz, QIAGEN's Chief Executive Officer. "QIAGEN significantly increased its strategic and operational strength and is expecting rapid growth in the research, clinical research, molecular diagnostics and applied markets. Douglas' leadership, expertise and experience in operations and strategic planning with leading companies of the molecular diagnostics industry will be a great contribution to further increase QIAGEN's operational excellence and thereby provide a strong operating basis for QIAGEN's anticipated future growth."




QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs more than 1,300 people worldwide. Further information on QIAGEN can be found at



Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products ( including fluctuations for certain events including funding, budgets, and others ), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).







Phone: +49 2103 29 11710

Fax: +49 2103 29 21710




Share this page